Homologous Recombination Deficient Diagnosis and PARP Inhibitor Therapy

Explore the role of genomic instability in cancer development and progression, focusing on inherited cancers and the impact of BRCA1 and BRCA2 gene dysfunction. Delve into the concept of Homologous Recombination Deficiency (HRD) and its significance in cancer treatment. Learn about PARP inhibitors as targeted therapies for HRD-associated cancers, examining their mechanism of action and supporting evidence. Discover diagnostic approaches for identifying individuals with HRD. Gain insights from expert presenter Dr. Brady Culver, Director of R&D Assay Development at Ambry Genetics, with moderation by Sarah Campian, MS, CGC, Genomic Science Liaison at Ambry Genetics.